Management of Emphysema

Introduction to Emphysema Management

• The American Thoracic Society recommends that smoking cessation is the single most important intervention in the management of emphysema, combined with bronchodilator inhalation, pulmonary rehabilitation, and long-term oxygen for severe hypoxemia 1, 2

Modifying Risk Factors

• The American College of Chest Physicians prioritizes smoking cessation as the primary focus for every patient visit, and reduction of occupational dust exposure, smoke, gases, and indoor and outdoor air pollutants is also crucial 1, 2

Pharmacological Therapy

• The Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommends that bronchodilator inhalation (beta-agonists and anticholinergics) reduces symptoms and improves health status in patients with emphysema 1
• Patients with airway eosinophilia show a better bronchodilator response to beta-agonists 2
• The European Respiratory Society suggests that bronchodilators should be used if there is airflow obstruction 3
• The American College of Chest Physicians recommends that oral corticosteroids are useful in patients with a clear asthma component, but should be used cautiously in the long term due to effects on bone loss 2
• The American Thoracic Society states that high bone loss contributes to lung volume loss and disability due to spinal pain 2
• The Infectious Diseases Society of America recommends that antibiotics should be used in patients with evidence of bronchitis or upper respiratory tract infection 2

Oxygen and Ventilatory Support Therapy

• The American Thoracic Society recommends that long-term oxygen therapy (>15 hours/day) improves survival in patients with resting severe hypoxemia 1
• The American College of Chest Physicians suggests that oxygen should be used in patients with desaturation during exercise 2
• The American Thoracic Society states that long-term oxygen therapy does NOT prolong time to death or first hospitalization in stable COPD patients with moderate arterial oxygen desaturation at rest or during exercise 1

Pulmonary Rehabilitation

• The American Association of Cardiovascular and Pulmonary Rehabilitation recommends that pulmonary rehabilitation improves endurance, reduces dyspnea, and reduces hospitalization rates in patients with emphysema 4, 2
• The program includes cardiovascular fitness development 5, increased confidence 5, and stress control 4, 2, 5

Management of Psychological Symptoms

• The American Psychiatric Association recommends that early signs of depression, such as loss of appetite, should be recognized and treated aggressively 4, 2
• The American College of Chest Physicians suggests that selective serotonin reuptake inhibitors (SSRIs) are effective for depression 5, 4, 2
• The American Thoracic Society states that tricyclic antidepressants may be poorly tolerated in patients with chronic sputum production 5, 4

Nutrition

• The American Thoracic Society recommends that weight loss and malnutrition are common problems in emphysema due to increased metabolic rate from increased work of breathing 4, 2
• The American College of Chest Physicians suggests that intensive nutritional support is largely unsuccessful in restoring ideal body weight 4, 2
• The American Thoracic Society states that eating small, frequent meals can reduce dyspnea by reducing abdominal bloating 4, 2

Surgical Interventions

• The American College of Chest Physicians recommends that lung volume reduction surgery (LVRS) improves survival in COPD patients with upper lobe emphysema and low post-rehabilitation exercise capacity compared to medical therapy 1, 6
• The American Thoracic Society states that contraindications for LVRS (higher mortality than medical management) include FEV1 ≤20% predicted and homogenous emphysema on HRCT 1, 6

Bronchoscopic Interventions

• The American Thoracic Society recommends that endobronchial valves improve FEV1 and 6-minute walk distance, but the magnitude of improvement is not clinically significant 1, 6
• The American College of Chest Physicians suggests that nitinol coils improve 6-minute walk distance compared to controls, with smaller improvements in FEV1 and quality of life 1, 6

Augmentation Therapy

• The American Thoracic Society recommends that augmentation therapy with human plasma-derived alpha-1 antitrypsin (60 mg/kg body weight once weekly) increases lung alpha-1 antitrypsin levels to 60-70% normal in patients with severe alpha-1 antitrypsin deficiency 5, 4, 2

Palliative Care

• The American Thoracic Society recommends that palliative care should focus on reducing dyspnea, pain, anxiety, depression, fatigue, and poor nutrition in patients with severe, unrelieved dyspnea 1, 6
• The American College of Chest Physicians suggests that discussions about end-of-life care should involve patients and their families, and advance care planning can reduce anxiety and ensure care consistent with patient preferences 6, 5

Evidence‑Based Management of Emphysema

Pharmacological Management

Bronchodilator Therapy

• In patients with mild emphysema, initiate short‑acting β₂‑agonist (SABA) or short‑acting antimuscarinic (SAMA) to relieve symptoms. – European Respiratory Society recommendation (moderate evidence) 7
• For symptomatic emphysema, prescribe a long‑acting β₂‑agonist (LABA) or long‑acting antimuscarinic (LAMA) as the preferred maintenance bronchodilator. – European Respiratory Society recommendation (moderate evidence) 7
• In highly symptomatic or frequent‑exacerbator patients, add a LABA + LAMA combination to further improve symptom control and reduce exacerbations. – European Respiratory Society recommendation (moderate evidence) 7
• Inhaled corticosteroid (ICS) + LABA combinations should be considered for patients who experience frequent exacerbations despite optimal bronchodilator therapy. – European Respiratory Society recommendation (moderate evidence) 7
• Bronchodilators improve exercise tolerance even when spirometric measures (e.g., FEV₁) do not show measurable change. – British Thoracic Society observation (low‑level evidence) 8
• Bronchodilator therapy is indicated whenever airflow obstruction is documented on pulmonary function testing. – European Respiratory Society guideline (moderate evidence) 9

Contra‑indicated Medications

• Ambrisentan is contraindicated in emphysema because it increases mortality and hospitalisation rates. – European Respiratory Society safety warning (high‑level evidence) 9
• Methylxanthines, aggressive hydration, chest physical therapy, and mucolytics lack proven benefit in emphysema and should not be prescribed. – American Academy of Allergy, Asthma & Immunology recommendation (moderate evidence) 10

Oxygen Therapy

• Short bursts of supplemental oxygen delivered from cylinders for transient breathlessness have no supporting efficacy data. – British Thoracic Society statement (low‑level evidence) 8

Pulmonary Rehabilitation

• Pulmonary rehabilitation programs improve endurance, reduce dyspnoea, lower hospitalisation rates, and enhance quality of life in symptomatic emphysema patients, even without measurable lung‑function improvement. – British Thoracic Society guideline (moderate evidence) 8
• Optimising bronchodilator therapy before initiating pulmonary rehabilitation maximises functional gains. – British Thoracic Society recommendation (moderate evidence) 8

Nutritional & Metabolic Management

• In obese emphysema patients, modest weight reduction decreases metabolic demand and improves exercise tolerance. – British Thoracic Society observation (low‑level evidence) 8

Vaccination

• Annual influenza vaccination reduces mortality in elderly patients with COPD/emphysema by approximately 70%. – British Thoracic Society recommendation (moderate evidence) 8
• Pneumococcal vaccination may be beneficial, although specific efficacy data for COPD/emphysema are lacking. – British Thoracic Society recommendation (low‑level evidence) 8

Screening & Comorbidities

• Screening for obstructive sleep apnoea with ventilatory polygraphy is advised when clinically suspected; prevalence can be as high as 88 % even in non‑obese emphysema patients. – European Respiratory Society recommendation (moderate evidence) 9
• In combined pulmonary fibrosis and emphysema, reliance solely on forced vital capacity (FVC) monitoring is insufficient because preserved volumes may mask disease severity. – European Respiratory Society guideline (moderate evidence) 9